KPV

The Transporter That Explains the Tripeptide

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

PepT1 is a proton-coupled transporter that carries di- and tripeptides across the intestinal epithelium. Dalmasso and colleagues showed in 2008 that KPV is one of its substrates, and that its reported anti-inflammatory activity in cell models depends on being carried inside by that route.

Key facts

Transporter
PepT1, gene SLC15A1
Substrate range
Di- and tripeptides, and peptidomimetic drugs
Driving force
Transmembrane electrochemical proton gradient
Normal expression
Small intestine; low in healthy colon
In inflammatory bowel disease
Induced in colon
Key paper
Dalmasso G et al., Gastroenterology 2008 (PMID 18061177)
Cells used
Caco2-BBE, HT29-Cl.19A, Jurkat T cells
Reported active range in vitro
Nanomolar

Why a transporter is the interesting part

Most of what is written about KPV starts from what it is a fragment of. That framing puts the emphasis in the wrong place. The single most reproducible finding in the KPV literature is not about melanocortin biology at all. It is that KPV is a substrate for PepT1, the di- and tripeptide transporter, and that its measured effects in cell models depend on that transport happening. Once you know that, the shape of the whole literature makes sense: why the work concentrates on the gut, why the molecule was given by mouth in animal studies when peptides usually cannot be, and why recent papers use KPV as a delivery handle for something else entirely. It also matters for the KLOW peptide stack, where KPV shares a vial with a second candidate PepT1 substrate.

What PepT1 actually does

Protein digestion does not end with free amino acids. A substantial share of absorbed nitrogen crosses the intestinal epithelium as intact di- and tripeptides, and PepT1 is the carrier that does it. It is an integral membrane protein of the proton-coupled oligopeptide transporter family, and it moves its substrates uphill against a concentration gradient by coupling transport to the inward movement of protons down the electrochemical gradient maintained at the brush border. Transport is electrogenic: charge moves with the substrate. The relevant consequence is that PepT1 has broad specificity, it recognises a shape and a charge distribution rather than a particular sequence,which is why it carries thousands of possible di- and tripeptides, and why it also carries peptidomimetic drugs that were never designed with it in mind.

Research material referenced

KPV 10mg, third-party HPLC tested

Buy KPV · £28.99

Why the colon matters here

PepT1 is normally expressed in the small intestine and is present in the healthy colon only at low levels. Dalmasso and colleagues note that it is induced in the colon during inflammatory bowel disease. That single detail explains why colitis models dominate this literature. A transporter that appears where and when inflammation appears offers something unusual: a route into cells that is upregulated in exactly the tissue and condition of interest. Whether that is a coincidence of biology or something functional is a separate question, and the same 2016 work that tested KPV against it found that the transporter's presence made colitis and its associated tumour burden worse in mice, not better.

What the 2008 experiments actually did

The design is worth setting out because it is stronger than the usual cell-culture study. Human intestinal epithelial lines Caco2-BBE and HT29-Cl.19A and a human T-cell line, Jurkat, were stimulated with pro-inflammatory cytokines with or without KPV, and the response was read out with an NF-kappaB luciferase reporter, Western blot, real-time RT-PCR and ELISA. Separately, transport was measured directly: unlabelled KPV was used as a competitor against a radiolabelled PepT1 substrate, and tritiated KPV was used to determine the kinetics of its own uptake. The reported effects on NF-kappaB and MAP kinase signalling occurred at nanomolar concentrations, and the authors conclude that KPV acts via PepT1 in both immune and epithelial cells.

Why competition plus labelled uptake is the right pair of experiments

Either experiment alone would be weak. Showing that cold KPV competes with a known PepT1 substrate says KPV binds something that substrate also binds. Suggestive, but competition can occur without transport. Showing that labelled KPV accumulates in cells says it gets in, but not by which route. Run together, they establish both that KPV interacts with the transporter's binding site and that KPV itself is carried, with measurable kinetics. This is the difference between asserting a mechanism and testing it, and it is why the 2008 paper remains the anchor of this literature nearly two decades later.

What this does not establish

That KPV does anything useful in a person. Everything above is cell lines and mouse models. Nanomolar potency in a luciferase reporter is a statement about a construct in a dish, not about a dose or an exposure in a human being. No clinical trial of KPV has been registered or reported. KPV is supplied here as a material for laboratory research only; it is not a medicine, it is not a treatment for any condition, and nothing in this literature should be read as suggesting otherwise.

Frequently asked questions

Is PepT1 the same as PEPT2?

No. They are related members of the same transporter family with different tissue distributions and different affinities. PepT1 is the high-capacity, lower-affinity intestinal carrier, while PEPT2 is the higher-affinity form found in kidney and elsewhere, including respiratory epithelium. Both are proton-coupled and both carry peptidomimetic drugs.

Does every tripeptide use PepT1?

Most di- and tripeptides are substrates to some degree, because the transporter recognises general features rather than a specific sequence. Affinity varies widely between sequences, and being a substrate is not the same as being a good one.

Does this mean KPV works orally?

It means the published animal studies administered it by mouth and the transporter provides a plausible route by which an intact tripeptide could be absorbed. That is a description of what researchers did in mice, not guidance. Nothing supplied here is for human use by any route.

Why does the transporter matter more than the receptor?

Because the evidence points that way. The transport route has been tested directly with competition, labelled uptake and a genetic knockout. A melanocortin receptor route has not been demonstrated for KPV, and the sequence gives good reason to doubt it.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More KPV articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.